Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01055314 · OUTCOME

Feasibility of the Addition of Cixutumumab to Chemotherapy Determined by Patient Enrollment

Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma · Source last updated 2017-08-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Proportion of Participants
Interval / dispersion
95% Confidence Interval
Time frame
From start to week 26 of therapy

What was measured

Proportion of no Grade 3+ cardiac toxicity.

Analysis population: 18 participants were excluded because of ineligibility or insufficient information to assess feasibility.

Groups in this outcome

IMC-A12

IMC-A12 + Multi-agent intensive chemotherapy regimen.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
IMC-A1282

Reported measurements

Source class 1
Values in Proportion of Participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
IMC-A120.9390Not reported0.88720.9908Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.8872
        upper Limit
        0.9908
        value
        0.9390
denoms
  1. counts
    1. group Id
      OG000
      value
      82
    units
    Participants
description
Proportion of no Grade 3+ cardiac toxicity.
dispersion Type
95% Confidence Interval
groups
  1. description
    IMC-A12 + Multi-agent intensive chemotherapy regimen.
    id
    OG000
    title
    IMC-A12
param Type
NUMBER
population Description
18 participants were excluded because of ineligibility or insufficient information to assess feasibility.
reporting Status
POSTED
time Frame
From start to week 26 of therapy
title
Feasibility of the Addition of Cixutumumab to Chemotherapy Determined by Patient Enrollment
type
PRIMARY
unit Of Measure
Proportion of Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice